Lorvotuzumab mertansine

{
  "id": "MLC-T-ONC-004935",
  "term": "Lorvotuzumab mertansine",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A substance being studied in the treatment of some types of cancer, including Wilms tumor, neuroblastoma, rhabdomyosarcoma, and other types of soft tissue sarcoma. Lorvotuzumab mertansine contains a monoclonal antibody that binds to a protein called CD56 on some types of cancer cells. It also contains an anticancer drug called DM1, which may help kill cancer cells after lorvotuzumab mertansine binds to them. Lorvotuzumab mertansine is a type of antibody-drug conjugate. Also called BB-10901.",
    "An immunoconjugate of a humanized murine monoclonal antibody (huN-901) and DMI, a semi-synthetic derivative of the plant-derived ansa macrolide maytansine. The antibody moiety of lorvotuzumab mertansine selectively attaches to CD56 antigen, a neural cell adhesion molecule (NCAM)) expressed on the surface of cells of small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors. Thus, the DMI conjugate is targeted specifically to CD56-expressing tumor cells, where it inhibits tubulin polymerization and assembly, resulting in inhibition of mitosis and cell cycle arrest in the S phase."
  ],
  "synonyms": [
    "BB-10901",
    "huN901-DM1",
    "IMGN901"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lorvotuzumab-mertansine/"
}